Literature DB >> 28974430

Predictive value of low interleukin-33 in critically ill patients.

Konstantin A Krychtiuk1, Stefan Stojkovic1, Max Lenz1, Mira Brekalo2, Kurt Huber3, Johann Wojta4, Gottfried Heinz2, Svitlana Demyanets5, Walter S Speidl2.   

Abstract

Patients admitted to a medical intensive care unit (ICU) are characterized by an activated immune system and exhibit a high mortality rate irrespective of the underlying cause of admission. Interleukin (IL)-33 has been shown to be protective in experimental sepsis models and it has been demonstrated that circulating levels of its "decoy" receptor soluble ST2 (sST2) are associated with outcome in critically ill patients. The aim of the present study was to investigate whether circulating IL-33 is associated with 30-day mortality in patients admitted to a medical ICU. In this prospective, observational study, both IL-33 and sST2 levels were assessed in 223 consecutive patients at ICU admission using specific enzyme-linked immunosorbent assays (ELISAs). During the 30-day follow-up, 58 patients (26%) died. Circulating IL-33 was detectable in 166 patients and in 57 patients, serum IL-33 was below the detection limit. Both detectable IL-33 and sST2 below the median were strong predictors of survival in critically ill patients independent of acute physiology and chronic health evaluation II (APACHE II) score. IL-33 and sST2 predicted risk independent from each other. Patients with both, non-detectable levels of IL-33 and sST2 levels above the median, showed a dramatically increased mortality risk (HR 6.9 95% CI 3.0-16.2; p<0.001). Low levels of IL-33 and increased levels of sST2 predict mortality risk in critically ill patients independent from each other and APACHE II score. Both together showed additive predictive value suggesting a pathogenic role of the IL-33/ST2 system in critically ill patients.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  30-day mortality; Critical care; Interleukin-33; SIRS; Soluble ST2

Mesh:

Substances:

Year:  2017        PMID: 28974430     DOI: 10.1016/j.cyto.2017.09.017

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  11 in total

1.  Cardioprotective cytokine interleukin-33 is up-regulated by statins in human cardiac tissue.

Authors:  Richard Pentz; Christoph Kaun; Barbara Thaler; Stefan Stojkovic; Max Lenz; Konstantin A Krychtiuk; Andreas Zuckermann; Kurt Huber; Johann Wojta; Philipp J Hohensinner; Svitlana Demyanets
Journal:  J Cell Mol Med       Date:  2018-09-14       Impact factor: 5.310

2.  Plasma levels of interleukin-33 and soluble suppression of tumorigenicity 2 in patients with advanced pancreatic ductal adenocarcinoma undergoing systemic chemotherapy.

Authors:  Markus Kieler; Matthias Unseld; Johann Wojta; Alexandra Kaider; Daniela Bianconi; Svitlana Demyanets; Gerald W Prager
Journal:  Med Oncol       Date:  2018-11-13       Impact factor: 3.064

3.  Association of Soluble Suppression of Tumorigenesis 2 (sST2) With Platelet Activation, Monocyte Tissue Factor and Ischemic Outcomes Following Angioplasty and Stenting.

Authors:  Stefan Stojkovic; Svitlana Demyanets; Christoph W Kopp; Christian Hengstenberg; Johann Wojta; Beate Eichelberger; Simon Panzer; Thomas Gremmel
Journal:  Front Cardiovasc Med       Date:  2020-12-22

4.  Soluble ST2 and All-Cause Mortality in Patients with Chronic Obstructive Pulmonary Disease-A 10-Year Cohort Study.

Authors:  Matthias H Urban; Stefan Stojkovic; Svitlana Demyanets; Christian Hengstenberg; Arschang Valipour; Johann Wojta; Otto C Burghuber
Journal:  J Clin Med       Date:  2021-12-23       Impact factor: 4.241

5.  Elevated Plasma Soluble ST2 Levels are Associated With Neuronal Injury and Neurocognitive Impairment in Children With Cerebral Malaria.

Authors:  Elizabeth M Fernander; Pontian Adogamhe; Dibyadyuti Datta; Caitlin Bond; Yi Zhao; Paul Bangirana; Andrea L Conroy; Robert O Opoka; Chandy C John
Journal:  Pathog Immun       Date:  2022-06-23

6.  Soluble suppression of tumorigenesis-2 is a strong predictor of all-cause, cardiovascular and infection-related mortality risk in haemodialysis patients with diabetes mellitus.

Authors:  Fabian Hammer; Bernd Genser; Benjamin Dieplinger; Margot Egger; Thomas Müller; Christiane Drechsler; Winfried März; Stefan Störk; Christoph Wanner; Vera Krane
Journal:  Clin Kidney J       Date:  2022-05-18

7.  GDF-15 is a better complimentary marker for risk stratification of arrhythmic death in non-ischaemic, dilated cardiomyopathy than soluble ST2.

Authors:  Stefan Stojkovic; Alexandra Kaider; Lorenz Koller; Mira Brekalo; Johann Wojta; Andre Diedrich; Svitlana Demyanets; Thomas Pezawas
Journal:  J Cell Mol Med       Date:  2018-02-04       Impact factor: 5.295

8.  The Role of Pro-Inflammatory and Regulatory Signaling by IL-33 in the Brain and Liver: A Focused Systematic Review of Mouse and Human Data and Risk of Bias Assessment of the Literature.

Authors:  Nika Zharichenko; Dolores B Njoku
Journal:  Int J Mol Sci       Date:  2020-05-30       Impact factor: 5.923

9.  IL-33 and ST2 as predictors of disease severity in children with viral acute lower respiratory infection.

Authors:  Carolina Augusta Arantes Portugal; Ítalo de Araújo Castro; Mirela Cristina Moreira Prates; Talita Bianca Gagliardi; Ronaldo Bragança Martins; Bruna Laís Santos de Jesus; Ricardo de Souza Cardoso; Marcus Vinícius Gomes da Silva; Davi Casale Aragon; Eurico Arruda Neto; José Carlos Farias Alves Filho; Fernando de Queiroz Cunha; Ana Paula de Carvalho Panzeri Carlotti
Journal:  Cytokine       Date:  2020-01-03       Impact factor: 3.861

10.  Role of Interleukin-33 in Staphylococcus epidermidis-Induced Septicemia.

Authors:  Min Yang; Yiwen Wang; Yonghong Zhang; Yanjun Li; Qifeng Li; Jintong Tan
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.